Compare Schlumberger NV (SLB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs State Street SPDR S&P Biotech ETF — how do they compare? Schlumberger NV trades at $46.77 (market cap $69.36B), while State Street SPDR S&P Biotech ETF trades at $154.41. The key difference: Schlumberger NV pays a 2.54% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Schlumberger NV nearer its low. Which is the better fit depends on your goals.
| SLB | XBI | |
|---|---|---|
Market Cap | $69.36B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $58.01 | $164.28 |
52-Week Low | $31.72 | $85.16 |
Enterprise Value | $77.58B | — |
Dividend Yield | 2.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $46.59, down 0.85% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with a 9.26% net margin and 14.57% ROE, supported by $6.5B in operating cash flow. Recent strategic moves include a partnership with Liberty Energy for data center power solutions and major contract wins like the Baleine Phase 3 EPC award, positioning SLB to capitalize on energy and AI infrastructure demand.
The outlook is cautiously optimistic with an 84.85% analyst buy rating and a $62.83 consensus price target implying 35% upside. Risks include oil price volatility and execution challenges in new ventures, but SLB's solid balance sheet and digital growth initiatives offer a compelling case for long-term investors amid near-term market weakness.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
